The 2017 event was a great success! – These are some of the testimonials:

“This is a great conference which covers most pricing topics with a decent amount of detail. Anyone can benefit from this conference no matter how experienced” – Sue Caleo-Naeyaert | Global Head Pricing, Market Access and Policy Biosimilars, Fresenius-Kabi SwissBioSim

“The EPP Life Sciences Pricing Forum is a unique event for learning about the latest pricing challenges and techniques to address them, due to the deep experiences and skills of the participants and speakers” – Ian Tidswell | Founder and Lead Consultant, een Consulting GmbH

“Exciting & energetic meeting where it is possible to learn, share & discuss best practices and new ideas on hot topics regarding pricing & tendering” – Giuseppe Monita | Senior Manager, Customer Services, Contracts & Tendering EMEA, BTG

“A good event for catching up, great networking and opportunity to share current thinking and best practice” – David Alderson, Director, Cogentia Healthcare Consulting

“A highly recommended forum for pricing professionals”Henderson Azevedo, Global Pricing Oncology, Bayer

“The 7th EPP Life Sciences Pricing Forum was the 3rd in a row that Alliance Life Sciences attended.  This year’s conference was the best yet in content. Participants come prepared to learn, share and together they helped shape the trends in our industry. The forum on the shores of Lake Geneva at the foot of the Alps is also the best locale you can imagine for a thought-provoking, content-rich conference. What a great atmosphere!” – Alan Crowther, President, Global Markets, Alliance Life Sciences

“In my experience, EEP is the only existing opportunity to discuss at 360 degrees about Pricing, involving both pharmaceutical and med tech stakeholders”Chiara Garavaglia, Partner, Global Leader of Tefen Life Sciences Centre of Excellence & Innovation, Tefen Management Consulting

Our Chairman’s Remarks: Michael Herepath | Managing Director – Optimal Access Life Science Consulting

It was a privilege and a pleasure for me to moderate this year’s EPP Life Science forum, and my thanks to EPP and their partners, to our first-class presenters and to all our engaged and enthusiastic participants for making this 7th forum such a great success. This year’s theme ‘Pricing for Value’ resonated very strongly with all who attended, and stimulated lots of high quality discussion and ideas sharing among the participants from both pharma and MedTech.

The quality of the plenary presentations, the panel discussions and the dedicated pharma and MedTech breakout sessions was particularly high, with industry leaders from across the globe tackling the key pricing issues facing life sciences today. These ranged from the role of pricing in value-based healthcare, through the out of pocket challenges of the emerging markets and the most effective ways to manage tendering, innovative contracting and using advanced data analytics, right through to harnessing the power of machine learning in pricing and contracting and how to successfully commercialize a pricing strategy.

Having been challenged to make the most of this learning opportunity that had been developed by pricing specialists for pricing specialists, it was so rewarding to see how actively everyone got engaged throughout the event, with lots of great probing questions and challenges for the presenters, many thought-provoking comments and points of discussion in the panel discussions and breakout groups, and loads of sharing of information, ideas and experiences during the coffee and lunch breaks and during the very enjoyable dinner event at Montrerux’ historic Museum Club. It was also great to see how the forum provided a golden opportunity for old colleagues and professional acquaintances to catch up, and for all the participants to make new contacts and grow their networks.

We began the forum by everyone making a note of what he or she wanted to take away from the event. From the feedback we’ve received so far, it’s clear that the vast majority of participants’ learning needs and expectations for the event were met and, in many cases, surpassed, with many participants declaring that the forum had been another great success and that they were looking forward to coming again next year.  I look forward to joining them!

If you would like to be part of this amazing forum next year, please contact us: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or call +32(0)473.71.76.69.

 

Pricing for Value

In its 7th year, our EPP Life Sciences Pricing Forum will once again bring together the best industry’s speakers, senior executives and innovators to discuss the latest developments in the pricing and profit optimisation area.

The event will give you the opportunity to learn, interact and network during 3 days of bootcamps, expert presentations, panel sessions, round tables discussions and exhibition area.

Join 100+ industry leaders in Pharma and MedTech in Europe’s main Pricing Forum dedicated to pricing strategy, payers relationships, price policy and innovative pricing tools.

The Forum’s agenda was created together with the industry, and we are very proud to announce that the 2017 event will include:

  • 4 ground-breaking bootcamps
  • 2 innovative workshops
  • 8 round tables discussions
  • 3 Panel Sessions
  • 2 Breakouts sessions: Pharma & MedTech
  • 25+ senior industry speakers sharing best practices and real case studies

If you would like to be part of this amazing forum next year, please contact us: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or call +32(0)473.71.76.69.

Watch our 2016 event video

 

If you would like to be part of this amazing forum next year, please contact us: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or call +32(0)473.71.76.69.

See the 2016 post forum report

 

If you would like to be part of this amazing forum next year, please contact us: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or call +32(0)473.71.76.69.

Download the 2017 brochure now!

 

 Room  P1180176  P1180617  P1180225
 P1180607  P1190219  P1190050  P1180175
 P1180226  P1180159  P1180280  P1180411

 


5 reasons why you should attend the EPP Life Sciences Pricing Forum in 2017

  1. 100+ senior level executives come together for exclusive keynote presentations, innovative bootcamps, 2 breakouts on Pharma and MedTech, workshops, round tables discussions and unrivalled networking to engage in high level business discussions that will shape the future of pricing
  2. The forum agenda was created together with key industry influencers to include the main industry’s challenges and opportunities
  3. 25+ Speakers delivering interactive workshops, round tables, panel discussions and ground-breaking presentations
  4. Pharma & MedTech Breakouts: Discuss, learn and challenge both strategic and tactical topics
  5. Networking: Face-to-face conversations with top industry experts and your pricing peers during the innovative and interactive forum format – you will meet and do business with the leading industry leaders

Who should be attending?

Every year 100+ attendees gather to discuss and reflect on the latest pricing and market access trends, learn about best business practices and meet world’s best experts in pricing and profit optimisation. The EPP Life Sciences Pricing Forum brings together leading practitioners and experts to discuss, reflect, network and share. The forum is tailored for value, know-how and a unique opportunity for key stakeholdes such as CFO/commercial controller/Pricing and market access leads and VPs /Commercial /Sales Ops /Marketing/CIOs/commercial IT

ATTENDING WITH 2+ GROUP :
contact: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or call +32(0)473.71.76.69.


This is an event you must attend!

  • 1 BUILD RELATIONSHIPS

    With more than 1000 minutes of network opportunity, you have plenty of time to connect with pricing colleagues from all over Europe.

  • 2 DISCUSS

    We stimulate an atmosphere of discussion and interaction, the best way to learn.

  • 3 LEARN FROM THE BEST

    A carefully selected speaking team of top pricing professionals, all active within your industry. No general talk, but only to-the point and useful presentations.

  • 4 REFLECT & PRACTICE

    Reflect on your key priorities and how to make it really happen !  Translate your key learnings into real change.

THE PROGRAMME

These are some of the topics included in the agenda:

  • Analysis of key Life Sciences pricing challenges and opportunities ahead
  • Market access and pricing models – how the future will evolve
  • The role of pricing in value based healthcare – How can we translate value into price?
  • Growing in Emerging Markets: The out of pocket challenge
  • Differential pricing & stakeholder engagement strategy
  • Biosimilars Overview: From adjusting to different market access policies to a successful market entry
  • Price and reimbursement for drug combinations – A new frontier in Market Access
  • Oncology market access challenges in the emerging markets
  • New types of contracts to obtain a fair reimbursement of your products
  • RWD and data validation – Understand how the authorities are evaluating products and their expectations of data evidence
  • How CPQ helps price strategies get executed
  • The successful commercialisation of a pricing strategy
  • Internal and external data to create competitive advantage and improve operation within tendering
  • Innovative pricing schemes based on outcomes
  • How advanced analytics can help spot price optimisation opportunities for a large portfolio of products across different markets
  • International Reference Pricing – How to ensure effective pricing strategies to maximise revenue

And more topics. See full programme here:

04 Oct
14:00-16:00
Bootcamp 1 – Focus on Tender Analytics –  An intense 2-hour hands on review of all major pricing tools and analytics techniques Alan Crowther - Alliance Life Sciences

Focus on Tender Analytics -  An intense 2-hour hands on review of all major pricing tools and analytics techniques: A complete review of tender pricing analytics, hands on exercises with a broad set of analytical pricing techniques, a collection and takeaway kit of KPIs and visualizations for understanding tender pricing performance.

04 Oct
14:00-16:00
Bootcamp 2 – Generate Real-World Evidence through partnerships with healthcare providers Paolo Correale - Tefen Management Consulting

Learn how to design partnership ideas and appropriately engage healthcare stakeholders, review some examples of successful partnerships, discuss implications for value-based pricing and access. Paolo Correale | Director, Leader of Tefen Life Sciences Pricing Practice and Chiara Garavaglia|Partner, Global Leader of Tefen Life Sciences Centre of Excellence & Innovation from Tefen Management Consulting

04 Oct
16:20-18:20
Bootcamp 3 – War gaming workshops in pricing strategy and tactics and lifecycle management David Alderson - Cogentia Healthcare Consulting

Can war gaming workshops help long term planning and tactical decision making around pricing? Review the theory and situations where a war game is applicable and useful Learn how to structure and set up a war gaming workshop - key factors for success and pitfalls to avoid Consider impact and potential benefits David Alderson, Director, Cogentia Healthcare Consulting

04 Oct
16:20-18:20
Bootcamp 4 – Is your organization ready for business transformation in the price to contract to settlement process? Derrick Herbst - Apttus

This can be your space to tell the industry about your innovative solutions and products. Contact Mariana Flores: mariana.flores@pricingplatform.eu
Learn how Configure Price Quote (CPQ) can prepare your organization for inevitable market disruption from price transparency, risk sharing and self-service. Identify CPQ value levers that drive strategic business outcomes. Learn how to gain visibility and control of your product, bundling and pricing strategy. What are the key pitfalls to avoid as you drive your organization further up the digital transformation maturity curve.

October 5th 2017
8:40-9:00 Chairman’s Opening Remarks

Welcome by EPP President – Pol Vanaerde | President, European Pricing Platform (EPP)
And Chairman of the event – Michael Herepath  |  Managing Director – Optimal Access Life Science Consulting

9:00-9:30 Session 1 · Pricing Landscape Today Market access and pricing models in Pharma and MedTech - Find out how the future can evolve Klaas Postema - Senior Director Market Access & Pricing Generics Europe, Teva
  • Gain a perspective of current pricing models and what the future looks like – Understand how the system is changing and why
  • Payers and sellers think in silos: Find out how as an industry we can design new pricing strategies to move from product to solution selling
  • Listen to real examples of how the Pharmaceutical and MedTech industries are joining forces and how this could change the future of Healthcare
  • Outcomes-based care is becoming central: Few proven methods to use current data and how this will truly shape our pricing models
9:30-10:00 Session 1 · Pricing Landscape Today The role of pricing in value based healthcare - How can we translate value into price? Richard Charter - Head of Market Access & Pricing BD Diabetes Care EMEA, Becton Dickinson
  • Understanding how the value assessment of medical devices is crucial for demonstrating value and pricing strategy. Contrasts to the pharmaceutical industry will be drawn, to capture the unique elements of medical device pricing
  • Learn how real-world data can demonstrate value and the impact that this has on pricing strategy in value based tenders and value based reimbursement scenarios
  • Achieve a win-win stakeholder partnership via patient access agreements, more commonly called risk sharing agreements, across the product lifecycle continuum
10:00-10:40 Session 1 · Pricing Landscape Today - Panel Session Discussion Key Life Science pricing challenges and opportunities ahead
  • Where is the industry going in terms of pricing? – Analysis of the current pricing environment and future
  • Hear the latest examples of how to build a strong stakeholder engagement to ensure market access and reimbursement
  • Learn how Pharma and MedTech create strong market access and pricing strategies to collaborate with payers with a value based approach

Giovanny Leon | Pricing & Market Access Director Latin America & Canada (LAC an), Novartis
Guy Nuyts | Senior Director Global Pricing, Janssen Pharmaceutical
Richard Charter | Head of Market Access & Pricing BD Diabetes Care EMEA, Becton Dickinson
Klaas Postema | Senior Director Market Access & Pricing Generics Europe, Teva
Youssef Mamour CPM | EMEA Pricing Director, Getinge

10:40-11:10 Coffee Break and Networking
11:10-11:40 Session 2 · Innovative Pricing - Opportunities and Challenges Growing in Emerging Markets - The out of pocket challenge in Pharma and MedTech industries Giovanny Leon - Pricing & Market Access Director Latin America & Canada (LAC an), Novartis
  • Understand why tailored pricing solutions for EM are required to achieve competitive growth
  • What are the key challenges to further growth in emerging markets?
  • The PAD methodology to measure affordability by decile
  • Our role attending the affordability challenge and the impact for the pricing strategy
11:40-12:10 Session 2 · Innovative Pricing - Opportunities and Challenges Differential pricing & stakeholder engagement strategy - Hear a successful case study from Janssen Guy Nuyts - Senior Director Global Pricing, Janssen Pharmaceutical
  • Find out how Janssen developed a product for a disease primarily prevalent in developing countries, how different stakeholders were taken into consideration and how the element of differential pricing affected the developing of the strategy – What did we learn that we can apply in Europe?
  • How do non-price barriers play a role in access
12:10-13:10 Lunch and Networking
13:30-15:10 Breakout Sessions Breakout Sessions
PHARMA 

Moderator: Giovanny Leon | Pricing & Market Access Director Latin America & Canada (LAC an), Novartis

MEDTECH

Moderator: Ian Tidswell | Founder and Lead Consultant, een Consulting GmbH

Biosimilars: From adjusting to different market access policies to a successful market entry

  • Understand how the different market access policies affect the entry of biosimilars
  • Hear real examples of how biosimilars entered new markets
  • What to consider in developing a pricing strategy for a biosimilar

Sue Caleo-Naeyaert | Global Head Pricing, Market Access and Policy Biosimilars, Fresenius-Kabi SwissBioSim

Boston Scientific: Our journey about pricing policy and approval process

  • How did we set up our internal pricing capability, governance and tools
  • What were the main challenges we faced and how we overcame them
  • A brief overview of what comes next in pricing

Simone Leone | Sales and Pricing Effectiveness Europe Director, Boston Scientific

Ana Ramos | Europe Pricing Manager, Boston Scientific

Price and reimbursement for drug combinations – A new frontier in Market Access

  • Why are drug combinations needed in novel treatments and what is different
  • Understanding the challenges to obtain reimbursement for drug combinations
  • What are the lessons learned from recent cases
  • Implementing sustainable price and reimbursement approaches for drug combinations

Henderson Azevedo | Global Pricing Oncology, Bayer

Strategic Pricing from a predictive analytics perspective

  • See how you can use powerful predictive analytics models to analyse all available product sales, pricing, and market data for countries, diseases, and therapeutic procedures to optimize pricing decisions
  • Identify the weight of pricing against other factors on revenue performance
  • Create interactive “what-if” future scenarios based on pricing or other business assumptions

George Boretos | CMO, Cube RM

Alternative pricing models for the future

The current model of pricing is under pressure. It leads to prices well above the social marginal cost which then impact optimal use and societal costs.

  • Analysis of alternative pricing models that have been proposed how these would impact incentives for manufacturers, payers and providers. These include pay for performance, risk sharing, capitation and subscription model.

Finn Ziegler | Director, Global Patient Access, LEO Pharma

 New types of contracts to obtain a fair reimbursement of your products

  • The reimbursement should reflect the innovation of the product – How can we ensure this using the right pricing model?
  • Pressure of the competitors – Find out the latest price aggressive strategies
  • Hear new types of contracts stating a value price and not a cost price

Youssef Mamour CPM | EMEA Pricing Director, Getinge

Round tables discussion

Current pricing policy challenges and approval process.

Moderator: Sue Caleo-Naeyaert | Global Head Pricing, Market Access and Policy Biosimilars, Fresenius-Kabi SwissBioSim

Implementation of sustainable price and reimbursement approaches.

Moderator: Henderson Azevedo | Global Pricing Oncology, Bayer

Alternative pricing models for the future.

Moderator: Finn Ziegler | Director, Global Patient Access, LEO Pharma

Round tables discussion

Current pricing policy challenges and approval process.

Moderators: Simone Leone | Sales and Pricing Effectiveness Europe Director, Boston Scientific
Ana Ramos | Europe Pricing Manager, Boston Scientific

Innovative Analytics models.

Moderador: George Boretos | CMO, Cube RM

New types of contracts to obtain a fair reimbursement of your products.

Moderator: Youssef Mamour CPM | EMEA Pricing Director, Getinge

15:10-15:40 Coffee Break and Networking
15:40-16:40 Workshops Workshops
Workshop 1:
The evolving healthcare valueframework: implications for pricing

  • Integrating value framework for pricing optimisation
  • Pricing to capture innovation value throughout the product lifecycle
  • Discussion of the implications of value framework using real case studies

Ian Tidswell | Founder and Lead Consultant, een Consulting GmbH

Carolin Miltenburger PhD | Payer Strategy Consultant Life Sciences, Independent Consultant

Workshop 2 :
Tender Management

  • Tender optimization strategy – Find out the latest cost containment strategies and reimbursement
  • Real examples of how successful tendering has been done in different countries in Europe and the procurement process – Are there any new rules about tendering?
  • What is your right data for tendering and how to source it
  • Optimizing your tendering process with data, a simple approach

Delivered by HighPoint Solutions

16:40-17:20 Panel session discussion Building strong partnerships with payers with current pricing models
  • RWD and data validation – Understand how the authorities are evaluating products and their expectations of data evidence
  • Risk sharing agreements – are they really working? – Analysis of examples in the industry and its financial and outcomes results
  • Evaluation of the value based concepts in practice – Analysis of the pros and cons according to payers and industry

Sue Caleo-Naeyaert | Global Head Pricing, Market Access and Policy Biosimilars, Fresenius-Kabi SwissBioSim
Adam Kundzewicz | PhD – Senior Global Payer Strategy Manager, Head of Pricing and Contracting, Boehringer Ingelheim
Daniel Watts | Director Systems Operations, Johnson & Johnson Health Care Systems
Giuseppe Monita | Senior Manager, Customer Services, Contracts & Tendering EMEA, BTG

17:20-17:40 Closing remarks of the chairman: Michael Herepath Michael Herepath - Managing Director at Optimal Access Life Science Consulting
October 6th 2017
8:40-9:00 Chairman’s Opening Remarks: Michael Herepath Michael Herepath - Managing Director at Optimal Access Life Science Consulting
9:00-9:30 Session 3 · Improving execution - Pricing Strategies Optimization How CPQ helps price strategies get executed Alan Crowther - President, Global Markets, Alliance Life Sciences
  • What is CPQ technology and how it is changing the ability to execute price strategy
  • Real world examples how CPQ impacted pricing and margins
  • Understand how CPQ enables more optimized pricing strategies
9:30-10:00 Session 3 · Improving execution - Pricing Strategies Optimization The successful commercialization of a pricing strategy Daniel Watts - Director Systems Operations, Johnson & Johnson Health Care Systems
  • What is CPQ technology and how it is changing the ability to execute price strategy
  • Real world examples how CPQ impacted pricing and margins
  • Understand how CPQ enables more optimized pricing strategies
10:00-10:30 Session 3 · Improving execution - Pricing Strategies Optimization Utilizing internal and external data to create competitive advantage and improve operation within tendering

Pharmaceutical and MD&D manufacturers continue to strengthen their competencies as it relates to Tendering due to internal and industry factors – maturity of products within their existing branded portfolio, increased competition within therapeutic classes, and continuing entry form Biosimilars. As such, organizations are not only looking to improve their people, processes, and technology, but also looking at information and data. Within this session, HighPoint will discuss industry trends as it relates to Tendering specifically focusing on ways manufacturers are using their own existing internal data and external from either providers or within the public domain to enhance existing operations and create competitive advantage.

Ruven Remo Eul | Associate Director, Life Sciences, HighPoint Solutions
Luca Morreale | Manager, Life Sciences, HighPoint Solutions

10:30-11:00 Coffee Break and Networking
11:00-12:30
 PHARMA  MEDTECH
Moderator: Giovanny Leon | Pricing & Market Access Director Latin America & Canada (LACan), Novartis Moderator: Daniel Watts | Director Systems Operations, Johnson & Johnson Health Care Systems
Innovative pricing schemes based on outcomes

  • The science-driven ongoing transformation of the industry and the impact on its business model
  • Use of Managed Entry Agreements (MEA s) to achieve sustainable pricing of pharmaceuticals: OECD and WHO positions, their adaptation at local level
  • Review of existing MEA s: current contracting approaches are predominantly finance-based
  • Developing outcome based approaches and promoting use of real world evidence to support PBR SA: initiatives (EU : EMA STA MP, US: FDA draft guidance)
  • PBR SA lifecycle: pre-contracting (improve the quality of financial assessment), execution (develop the logistics of data collection)
  • Identify the best operating model: private, public, public-private partnership

Bertrand Tardivel | Head of Global Pricing, Takeda Pharmaceuticals

How to execute a consistent distributor pricing model: a case study in emerging markets

  • Learn how to define an efficient process streamlining company and distributor activities
  • How to calculate Target ASP based on Country/Franchise drivers and historical Net ASP
  • Design pay-for-performance schemes to ensure distributor alignment with company’s commercial strategy
  • How to set clear guidelines for price exception management

Paolo Correale | Director, Leader of Tefen Life Sciences Pricing Practice, Tefen Consulting

Managed entry agreements in Belgium – a system with threats, and high potential, if properly applied. What can we learn and apply in other countries in Europe?

  • The Belgian Health Care Knowledge Centre (KCE), an independent federal agency providing advice to policy makers, was asked to assess the strengths and weaknesses of the ‘managed entry agreements (MEA)’ procedure in Belgium and to identify the areas where there is room for improvement. The entire process leading to MEAs was involved, starting with the standard reimbursement procedure up to the end of the MEA and the possible renewal. In this presentation, we focus on some observations and especially the threats and opportunities related to this system of confidential reimbursement agreements.

Mattias Neyt (MSc, PhD), Senior expert, Belgian Health Care Knowledge Centre (KCE)

Meet MAX – Putting the power of machine learning and Intelligent Agents to work in pharma/medtech pricing and contracting scenarios

Cloud technology and related innovations such as smart agents and machine learning create a powerful intersection for run-time pricing and contracting decisions while having deep implications for the future of on-demand and just-in-time deal support. Apttus is working with a cross-section of industry leaders to shape the use cases that matter to pricing and contracting, sales and service leaders. Attend this session for a practical discussion of key capabilities made possible with intelligent agents such as Max and how they can add value to the adoption of current and next generation pricing, contracting and tendering processes.

  • Self-service in the age of anytime, anywhere cloud
  • Machine learning for guided contracting and pricing decisions
  • Single data model and modular applications

Gopkiran Rao | Senior Vice President of Quote-to-Cash solutions, Apttus

Alan Crowther | President, Global Markets, Alliance Life Sciences

Round tables discussion

Innovative pricing schemes based on outcomes.

Moderator: Bertrand Tardivel | Head of Global Pricing, Takeda Pharmaceuticals

Managed entry agreements

Round tables discussion

How to execute a consistent distributor pricing model.

Moderator: Paolo Correale | Director, Leader of Tefen Life Sciences Pricing Practice, Tefen Consulting

Key capabilities made possible with intelligent agents such as Max and how they can add value to the adoption of current and next generation pricing, contracting and tendering processes.

Moderator: Derrick Herbst| Principal, Solution Engineering – Pricing & Machine Learning, Apttus

12:30-13:30 Lunch and Networking
13:30-14:00 Session 3 · Improving execution - Pricing Strategies Optimization How advanced analytics can help spot price optimization opportunities for a large portfolio of products across different markets
  • Find out how to identify pricing optimization in a very large portfolio of mature products across different markets
  • Estimation of pricing power per product/market combination
  • KPIs to monitor pricing performance of mature products

Halima Benghabrit | Global Pricing Director, Sanofi
Marc Abels | Partner, Deloitte

14:00-14:40 Session 3 · Improving execution - Pricing Strategies Optimization - Panel Session Discussion International Reference Pricing - How to ensure effective pricing strategies to maximize revenue

International Reference Pricing – How to ensure effective pricing strategies to maximize revenue

  • Find out the latest rules of IR P and how these will impact your pricing models
  • What is the fair price for our product? – An industry analysis and discussion
  • Analysis of the impact of IR P and discussion of the strategies to mitigate the challenges

Halima Benghabrit | Global Pricing Director at Sanofi, Sanofi
Richard Waygood | Senior Manager, International Pricing & Tender Strategy, Baxter Healthcare SA
Adam Kundzewicz | PhD – Senior Global Payer Strategy Manager, Head of Pricing and Contracting, Boehringer Ingelheim
Finn Ziegler | Director, Global Patient Access, LEO Pharma
Giuseppe Monita | Senior Manager, Customer Services, Contracts & Tendering EMEA, BTG

14:40-15:10 Closing remarks of the chairman: Michael Herepath Michael Herepath - Managing Director at Optimal Access Life Science Consulting

Contact Forum Producer

Mariana Flores

BOOTCAMPS

During day one, you choose your 2 (between 4), interactive, bootcamps.

Bootcamp 1 – Focus on Tender Analytics –  An intense 2-hour hands on review of all major pricing tools and analytics techniques

Focus on Tender Analytics -  An intense 2-hour hands on review of all major pricing tools and analytics techniques

04Oct14:00-16:00

  • Focus on Tender Analytics -  An intense 2-hour hands on review of all major pricing tools and analytics techniques: A complete review of tender pricing analytics, hands on exercises with a broad set of analytical pricing techniques, a collection and takeaway kit of KPIs and visualizations for understanding tender pricing performance.

Alan Crowther (USA) Alliance Life Sciences

MORE INFO »

Bootcamp 2 – Generate Real-World Evidence through partnerships with healthcare providers

Generate Real-World Evidence through partnerships with healthcare providers

04Oct14:00-16:00

  • Learn how to design partnership ideas and appropriately engage healthcare stakeholders, review some examples of successful partnerships, discuss implications for value-based pricing and access. Paolo Correale | Director, Leader of Tefen Life Sciences Pricing Practice and Chiara Garavaglia|Partner, Global Leader of Tefen Life Sciences Centre of Excellence & Innovation from Tefen Management Consulting

Paolo Correale (Italy) Tefen Management Consulting

MORE INFO »

Bootcamp 3 – War gaming workshops in pricing strategy and tactics and lifecycle management

04Oct16:20-18:20

  • Can war gaming workshops help long term planning and tactical decision making around pricing? Review the theory and situations where a war game is applicable and useful Learn how to structure and set up a war gaming workshop - key factors for success and pitfalls to avoid Consider impact and potential benefits David Alderson, Director, Cogentia Healthcare Consulting

David Alderson (United Kingdom) Cogentia Healthcare Consulting

MORE INFO »

Speaker Faculty 2017

This is the speaker line-up of the 2017 edition of the EPP Life Sciences Pricing forum. If you would be interested to share your expertise or discuss with focus groups about your industry challenges for next year's edition, please send your contact details and session suggestions to mariana.flores@pricingplatform.eu.

Alan Crowther (USA)

President, Global Markets - Alliance Life Sciences Alliance Life Sciences


Alan Crowther is President, Global Markets of Alliance Life Sciences, responsible for overseeing the Global Pricing solutions for Alliance. He brings 20 years of leadership, consulting and technology experience with him to the position. Alan has previously held roles as CEO at Alliance; founder of Adjility Health, a firm focused on life sciences analytical software; Vice President at Capgemini; Co-founder and Officer at Adjoined Consulting, where he ran the Life Sciences practice and was part of the leadership of the venture-backed company and helped drive it to a successful $200MM+ exit. Prior to Adjoined, Mr. Crowther was head of services for a small software company that exited to BEA Systems; and was a manager at Andersen Consulting (Accenture) before that. He is a graduate of Princeton University.

 

ASK A QUESTION

Ana Ramos (Portugal)

Europe Pricing Manager Boston Scientific


Ana’s key responsibility at Boston Scientific is to support the development and implementation of processes and solutions that optimize pricing execution, visibility and governance allowing the business to reflect their products and services value while maximizing profit.

Additionally, she is Country Coordinator for BSC Portugal. This responsibility includes leading the organization in the execution of business goals, ensuring alignment across functions and ensuring European programs and initiatives are embedded in the country.

In the past Ana had different roles in organization as Europe Business Finance Manager of the Endoscopy business leading the development and implementation of the European pricing program, Finance and Planning Analyst for Iberia and Financial controller for Portugal.

Prior to joining BSC, she held positions at Guidant and St. Jude Medical. Ana has a post graduate degree in Tax Management, a degree in Audit and Accounting and is a Certified Accountant.

ASK A QUESTION

Daniel Watts (USA)

Director of System Operations - Contracting Competency Center Johnson & Johnson Health Care Systems Inc.


With 15 years of experience in the Health Care and Life Sciences industry, Daniel has experience in both the Pharmaceutical and Medical Device sectors. Daniel’s 12 year tenure in the Contract and Pricing area includes Project, Program, and Portfolio Management with time spent supporting Global Enterprise Programs. Recently Daniel has Revenue Management System implementation experience in the Asia Pacific region. Currently Daniel is involved with process and system evaluation or system implementations in multiple countries in North America and Europe. Daniel has also taken on leadership roles in sector-wide initiatives for the improvement of contracting practices and adoption of technology or data standards. Daniel holds degrees in Computer Science and Business Management and is a certified PMP.

 

 

ASK A QUESTION

STEERING COMMITTEE FOR THE LIFE SCIENCES INDUSTRY

SPEAKERS FACULTY

Julie Spiesser (France)

Associate Vice President Global Strategic Pricing Sanofi


About Julie

Julie Spiesser is a Health Economist specialized in Market Access and Pricing. She has been working for the Pharma industry since 15 years. She started her carreer at Sanofi R&D working in Psychiatry and Cardiovascular area. She joined the Sanofi European team as Senior Market access Manager and took later on the position of European Outcomes Research Director at Pfizer for anti-infective Disease Area. And since 2010 she is heading the Global Strategic Pricing team of Sanofi.

Tsveta Milanova (USA)

VP Corporate Pricing & Market Access Celgene


About Tsveta

Tsveta Milanova works at Celgene EMEA for six years now, most recently as VP Corporate, Pricing and Market Access. She has led numerous workshops with leading industry experts and also developed market access strategies for pre-launch products and new indications.

Photo Daniel Cho

Daniel Cho (Germany)

Director Marketing, Global Pricing & Competitive Portfolio Analytics - Patient Care and Monitoring Solutions Philips Healthcare


About Daniel

Daniel Cho is currently the Director of Global Pricing for Patient Care and Monitoring Systems, a 3B Euro Business Group under Philips Healthcare. He heads a team of Pricing Managers to use Pricing as a tool to maximise the profitability of PCMS by better manage the Creation, Capturing and Maintenance of the values PCMS can deliver to their end customers.

Sara Aswegan (Switzerland)

Senior Vice President Ultragenyx Pharmaceuticals Inc.


About Sara

Sara has recently joined Ultragenyx Pharmacuetical Inc. as Senior Vice-President. Before that she led the Product Strategy Teams for the MPS II Business in the Rare Disease Business Unit, supporting the second largest revenue contributor for Shire, as well as plans for commercial success with the development products for Hunter CNS.

Adam Plich (The Netherlands)

VP, Head of Pricing & Market Access Europe TEVA Pharmaceutical Europe


About Adam

Adam has been working with Teva since 2012 as Head of Pricing and Market Access, first based in London now in Amsterdam.  Teva Pharmaceutical is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products.

Finn Ziegler (Denmark)

Director, Global Patient Access LEO Pharma


Finn has recently joined LEO Pharma, after having worked for 6 years as International Contracts and Pricing Manager with Amgen, responsable for pricing and contract strategy and implementation.

His specialties lie in the domain of pricing research & strategies, health economics, public procurement and reimbursement of pharmaceuticals, public policy & affairs, think tanks, parallel trade and reference pricing in the pharmaceutical industry

 

Gustavo Saraiva (UK)

Head of Pricing and Access Intelligence Otsuka Pharmaceuticals Europe


About Gustavo

Gustavo is the head of the Pricing and Access Intelligence at Otsuka Pharmaceuticals Europe, where he is in charge of developing the pricing strategies for the entire product portfolio as well as providing business intelligence insights to the global organisation. His previous years indicate his wealth and expertise in the finance industry before transitioning into Pricing and Market Access. Prior to joining Otsuka he worked with LEO Pharma for three years as a Global Pricing Manager where he had to manage both strategic and operational pricing at a global and local level. Gustavo graduated in Business administration and has a Masters degree in Finance from NOVA School of Business and Economics in Lisbon – Portugal. He also holds an MBA from Universidade Federal Fluminense in Rio de Janeiro – Brazil.

Alan Crowther (USA)

President, Global Markets - Alliance Life Sciences Alliance Life Sciences


Alan Crowther is President, Global Markets of Alliance Life Sciences, responsible for overseeing the Global Pricing solutions for Alliance. He brings 20 years of leadership, consulting and technology experience with him to the position. Alan has previously held roles as CEO at Alliance; founder of Adjility Health, a firm focused on life sciences analytical software; Vice President at Capgemini; Co-founder and Officer at Adjoined Consulting, where he ran the Life Sciences practice and was part of the leadership of the venture-backed company and helped drive it to a successful $200MM+ exit. Prior to Adjoined, Mr. Crowther was head of services for a small software company that exited to BEA Systems; and was a manager at Andersen Consulting (Accenture) before that. He is a graduate of Princeton University.

 

Richard Fergusson (Switzerland)

EMEA Director of Strategic Pricing BD


About Richard

Richard has 15 years of experience in the Medical Technology industry, in various sales, marketing and strategy roles, with the majority of this time closely connected to the topic of Strategic Pricing. Richard is currently the EMEA Director of Strategic Pricing for Becton Dickinson, a global manufacturer of diagnostic and drug delivery devices. During his 4 years at the company he has led a program to build and shape strategic pricing capabilities across the region, as well as taking responsibility for building the regional Health Economics function and for various global pricing programs focused on implementation and adoption of pricing related systems and harmonised processes. Richard started his career as a medicinal chemist, spent a number of years as a management consultant with Andersen prior to completing his MBA at Leeds University Business School, during which time he worked closely with academics and local business incubators to research the topic of technology transfer. He has recently returned to academia to study part time for a Masters in International HTA and healthcare reimbursement at the University of Sheffield.

 

Bertrand Tardivel (Switzerland)

Head of Global Pricing Takeda Pharmaceuticals


Bertrand is the Head of Global Pricing at Takeda. He joined Takeda when the company started its transformation to a specialty care Pharma company 4 years ago. Bertrand has developed his expertise in a variety of new therapies in Onco-Hemato and GI spanning from chemicals to biologics and, more recently, new therapies based on stem cells.

Bertrand has a broad understanding of the Pharma industry, gained in the various roles he has held in Life Sciences, prior to joining Takeda.  He has extensive experience in Finance, Forecasting and Business Development in both pharmaceutical companies and consulting positions.

Chiara Garavaglia (Italy )

Partner, Global Leader of Tefen Life Sciences Centre of Excellence & Innovation Tefen Management Consulting


Chiara is a Partner at Tefen Europe and Global Leader of Tefen Life Sciences Centre of Excellence & Innovation. She has been working for more than 20 years in consulting, with key focus on medical devices, pharmaceutical and healthcare areas.

More than ten years ago, Chiara pioneered an innovative Healthcare Partnership approach, developing a large network of Life Sciences and Healthcare companies and supporting them in establishing win-win solutions.

During her professional path, she created leading-edge offerings and expertise in Healthcare Solutions, Multichannel, New Product Launch, Pricing, Commercial Excellence and executed projects at local and global level for more than fifty companies amongst the largest Life Sciences companies in the world.

She also supports med-tech start-ups and operates as advisory for investment funds and venture capitals.

 

Mattias Neyt (Belgium)

Senior expert (MSc, PhD) Belgian Health Care Knowledge Centre (KCE)


Mattias Neyt (MSc, PhD) is a Senior Health Economist working since 2005 for the Belgian Health Care Knowledge Centre (KCE). Graduated in 2000 as an economist at Ghent University. Obtained in 2006 his PhD in health economics/pharmacoeconomics. Co-author of more than 30 Health Technology Assessment (HTA) and Health Services Research (HSR) reports and about 50 peer-reviewed journal articles about drugs, devices, diagnostics, screening, etc.. Co-author of the Belgian guidelines for economic evaluations and European guidelines for measuring health-related quality of life. Teacher in health economics (HUB-EHSAL). Independent researcher at ME-TA (Medical Evaluation and Technology Assessment) that conducts systematic reviews and HTAs for foreign non-profit organizations and provides professional training.

David Alderson (United Kingdom)

Director Cogentia Healthcare Consulting


David leads the Pricing and Strategic Market Access practice at Cogentia, a  specialist market access and health economic consulting company. Over the last 25 years in the lifescienes industry, David has worked for GSK, Novartis, and Medimmune (Cambridge Antibody Technology), as well as Mundipharma and several market access consulting companies. Since 2009 David has been consulting in market access, leading projects and teams involved in payer research, pricing, strategic market access, value communication and proposition development, as well as advisory boards and training workshops. David has a MBA from Cranfield, and postgraduate Marketing Diploma (Chartered Institute of Marketing), and is also a Chartered Engineer (IMechE).

Gopkiran Rao (USA)

Senior Vice President of Quote-to-Cash solutions Apttus


Gopkiran Rao, Senior Vice President of Quote-to-Cash solutions, Apttus, has worked with Fortune 500 companies in consulting and software management roles across strategic sales and pricing management initiatives and application of technology and analytics best practices in complex, multi-channel and regulated industry settings. At Apttus, he is responsible for targeted industry solutions drawing on 18 years of experience including defining, delivering and implementing pricing and contract management solutions for leading pharmaceutical and medical technology manufacturers.

Derrick Herbst (USA)

Principal, Solution Engineering - Pricing & Machine Learning Apttus


Derrick has over 20 years of experience in pricing management in various sales, marketing, strategic planning and consulting roles in large B2B enterprises.  Derrick joined Apttus in March 2015,  as an Account Executive on the East Commercial  team and then moved to the Principal, Solution Engineering – Pricing & Machine Learning role in September, 2016.

Prior to joining Apttus, Derrick was with Vendavo for  9+ years, initially in the Business Consulting group where he worked with prospects to understand their pricing requirements/needs, how the Vendavo solution could address/meet those needs, developed solution proposals and performed related demonstrations, developed business cases, and worked with customers in the Requirements process to transfer the learnings’ of the sales cycle to the implementation team.  Derrick moved to the National Account Executive role at Vendavo in early 2010 and successfully led several enterprise sales engagements and the business development effort of Vendavo’s first SaaS solution by leveraging his knowledge and first-hand experience in pricing.

WHAT ATTENDEES LIKE ABOUT THIS EVENT

“A conference really dedicated to Pricing”

Clotilde Noble, at Ferring Pharmaceuticals

Excellent conference with very interesting topics and excellent speakers. I attempted this conference two times and I would like to participate to the next one.

‘I enjoyed the opportunity to meet, listen to and network with pricing professionals.’

Raj Kanapathy, at Siemens Healthcare

I enjoyed the opportunity to meet, listen to and network with pricing professionals in the Life Science industry and would definitely recommend the experience to other pricing professionals.

“It’s much more lively and interactive!”

Madalina Preda, European Pricing Supervisor at Corning BV

It is much more lively and focussed on burning issues in the Life Science markets.

Meet pricing decision makers from:

VENUE

Grand Hotel Suisse Majestic – 4*deluxe

This majestic hotel was originally built during the Belle Epoque in 1870 and entirely renovated in 2010. The hotel is just on the lakefront and so you get a phenomenal view of the lake, the promenade, the gardens and of course the snow capped mountains.   Take a look at this splendid hotel !

Please note that we have a limited number of rooms at preferred rates at our disposal : contact Britt Dejager on britt.dejager@pricingplatform.eu to book now !

Avenue des Alpes 45, 1820 Montreux, Zwitserland- +41 21 966 33 33 – hotel website

The easiest way to get to Montreux is to take the train from Geneva Airport direct to Montreux (CHF 35.-/ 2nd class and CHF 62.-/ 1st class)
There is a direct train every 20 minutes (http://www.sbb.ch/en/timetable.html ) – the hotel is straight across the train station.
A taxi will be about CHF 350.-

Photo Grand Hotel Suisse Majestic

Snow capped mountains…

Grand Hotel Suisse Majestic5

…with a great view to the lake…

Grand Hotel Suisse Majestic3

…all comfort in the Belle Epoque…

P1180175

Share, learn and discuss

Grand Hotel Suisse Majestic4

…in an inspiring environment.

P1180607

Perfect work-pleasure combination!

CONTENT

Download HPS White Paper Tender Management

Tender Management by Highpoint Solutions

Tenders are a specific form of centralized procurement:

Either by public health authorities, purchasing organizations or private chains acting as issuing bodies. The majority of countries and healthcare authorities continuously face shrinking budgets and therefore have looked to the cost-saving potential of T&C concepts for their respective countries. All of these issuing bodies have a formal and structured procurement process to obtain several benefits.

In this white paper you will learn:

  • Benefits of Implementing T&C for Healthcare Authorities
  • Benefits of Implementing T&C for Life Sciences

Download Pricing challenges in MedTech

The challenges facing the MedTech market and actions manufacturers can take to address these challenges:

MedTech implications of Healthcare spending.

How Healthcare spending be reallocated?

Where do products and innovations add value?

The impact of innvovation on Healthcare stakeholders.

Find the answers to these questions in the  presentation delivered by Ian Tidswell, Founder and LeadConsultant at een consulting GmbH.

 

Simply fill in your details to download the thought leadership content.

 

EPP PARTNERSHIPS

MEDIA PARTNERS

REGISTRATION

Register Now!

*prices in EURO

FULL CONFERENCE PASS
1995
4-5-6 OCT
Access to the bootcamps (day 1)
Access to the 2 days forum
Access to evening event
PDF presentations after event
FORUM PASS
1695
5-6 OCT
 
Access to the 2 days forum
Access to evening event
PDF presentations after event
 
BOOTCAMPS PASS ONLY
645
4 OCT
Access to your selected bootcamps
 
 
 
 

Group discounts are available of > 2 people
Inquire

GOLD FORUM PASS
2995
4-5-6 OCT
Access to the 2 days forum
Access to evening event
PDF presentations after event
SILVER FORUM PASS
2695
4-5-6 OCT
Access to the 2 days forum
 
 
GROUP RATES
on demand
Group discounts of > 2 people